Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A synthetic tripeptide (Glu-Asp-Arg) developed by the St. Petersburg Institute of Bioregulation and Gerontology — the same institution behind Epitalon. Pinealon is designed to target the central nervous system and pineal gland, with research focused on neuroprotection, cognitive function, and circadian rhythm regulation.
A synthetic heptapeptide analog of ACTH(4-10) developed in Russia, where it has been used clinically for decades to treat cerebral ischemia and cognitive impairment. Growing interest in the West for nootropic and neuroprotective applications.
Penetrates the blood-brain barrier and accumulates in neurons. Modulates gene expression related to neuronal survival and function. Reduces oxidative stress in neural tissue. Appears to regulate melatonin synthesis through pineal gland activity, supporting circadian rhythm normalization.
Activates BDNF (brain-derived neurotrophic factor) and its receptor TrkB, promoting neuronal survival, synaptic plasticity, and cognitive function. Also modulates serotonergic, dopaminergic, and adrenergic systems. Reduces oxidative stress and neuroinflammation.
- Cognitive enhancement and memory
- Neuroprotection
- Sleep quality improvement
- Age-related cognitive decline
- Stroke recovery support (preliminary research)
- Cognitive enhancement and focus
- Neuroprotection after stroke or ischemia
- Anxiety and depression support
- ADHD symptom management
- Memory and learning improvement
- Very limited independent Western research
- Most studies from Russian institutions
- Long-term safety unknown
- Mechanism not fully characterized
- Injection site reactions
- Limited Western clinical trial data
- Nasal spray form may cause irritation
- Potential stimulant-like effects
- Headaches reported
- Long-term safety profile unknown in Western populations
Not FDA-approved and not on any compounding list. Available as a research chemical. Research base is almost entirely from Russian institutions — independent replication is limited. Not affected by the 2026 regulatory changes.
Removed from FDA 503A Category 2 effective April 22, 2026. Scheduled for PCAC review on July 24, 2026. Has extensive clinical use in Russia for cerebral ischemia and trigeminal neuralgia, but limited US clinical trial data. Compounding not yet authorized — status is in regulatory gray zone pending PCAC recommendation.
PCAC: July 24, 2026
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.